Michel Vounatsos, Biogen CEO (via YouTube)

Bio­gen yanks its Aduhelm ap­pli­ca­tion in Cana­da, days af­ter cel­e­brat­ing the drug's 1-year an­niver­sary in the US

Add Cana­da to the list of coun­tries where Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm isn’t want­ed by health of­fi­cials.

The biotech an­nounced on Thurs­day that it’s pulling ad­u­canum­ab’s new drug sub­mis­sion (NDS) in Cana­da af­ter the coun­try’s health agency in­di­cat­ed that “the da­ta pro­vid­ed would not be suf­fi­cient to sup­port a mar­ket­ing au­tho­riza­tion.”

The news comes just a cou­ple of months af­ter Bio­gen pulled ad­u­canum­ab’s ap­pli­ca­tion in Eu­rope, where reg­u­la­tors re­ject­ed it late last year — and al­most a year to the date since the drug won its high­ly dis­put­ed ac­cel­er­at­ed ap­proval in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.